drugset
drugset / Trial / NCT02176031

Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD

NCT02176031 ↗

Phase 2 Completed 21 enrolled Dana-Farber Cancer Institute Biogen · collab
NaSingle-groupOpen-labelTreatment

Summary

This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug Natalizumab in treating Acute Graft-Versus-Host Disease (GVHD) in the Gastrointestinal (GI) Tract.

Timeline

Start
2015-01
Primary completion
2019-02
Completion
2019-02

Drugs

EvaluationDrugModalityDoseRoute
Subject natalizumab Monoclonal antibody — Intravenous
Background Methylprednisolone Other / unclassified — —

Indications

acute graft versus host disease